BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase
BioMarin $BMRN has taken a big step toward a final FDA decision on its latest rare disease drug to reach regulators. The agency
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
